Drug Candidate Marketplace
Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. After consenting to the terms of condition and use of our services, the requested information will be provided to you.
|Date||Candidate||Mechanism of action||Indication||Route||Development stage||Note|
|12/27/18||GEM057||Increase hair follicle ATP and delay senescence of dermal papilla cells||Alopecia||Topical||Phase 2||Boosts the ATP of human follicle dermal papilla cells, thereby slowing down the aging speed and prolonging hair cycle.
No side effects and shorter time to observe efficacy
Human trial (Androgenetic Alopecia): significantly improved 37.5% vs 0% (placebo) during 2 months
Phase 2 (Female pattern hair loss) : ongoing (comparison with minoxidil)
|12/20/18||GEM056||Novel PDL1/CDx bispecific antibody||Cancer with T cell inactivation and CDC inactivation||Infusion||Preclinical||First bispecific combining the following two mechanisms: 1) Release cancer repression on T cell activation not only by blocking PDL1/PD1 interaction, but also by inducing PDL1 internalization into cancer cells; 2) Release cancer repression on CDC by downregulation of CDC repressor overexpressed by cancer cells (CDx is a CDC repressor overexpressed by multiple cancers, this bispecific can induce CDx internalization on cancer cells).||Contact|
|12/20/18||GEM055||Novel CD20/CD3 bispecific antibody||Rituxan resistant cancer||Infusion||Preclinical||Unique features by computational designed bispecific antibody:
1) Better safety to reduce CDR: T cell activation and T cell killing are only detected in the presence of target cancer cell
2) Multiple MOA to target cancer heterogeneity: Extremely low CD3 binding enables “safe maintenance" of ADCC/CDC in addition to T cell killing. This BsAb can delay cancer relapse compared to Rituximab
3) Better developability : More than 95% of heterodimer formation due to novel Fc mutations on top of a pair of "knob into hole", designed biochemical and biophysical difference between the two arms enables easier purification.
|12/13/18||GEM054||Intracellular superoxide removing agent||Please refer to Note||IV||Phase 2||Indication: Chemotherapy induced Peripheral Neuropathy (CIPN)
Note: There is currently no approved drug to prevent or treat CIPN.
Completion of Phase 2b study.
Global Phase 3 started in US, Currently in preparation for Phase 3 in Japan, South Korea, Taiwan and Hong Kong.
Can be licensed to Japan, South Korea, Taiwan and Hong Kong.
|12/13/18||GEM053||Substance for covering oral lesions (no active ingredients: medical device)||Control and relief pain of oral mucositis by chemotherapy/ radiotherapy||Local||Launch||There is no standard treatment for chemo/radiotherapy induced mucositis–high unmet medical needs.
Forms a mucoadhesive barrier film when applied in the oral cavity. Excellent control of oral pain (rapid and long-lasting effects and ready to use)
Can be licensed to Korea.
|12/13/18||GEM052||Mitochondria-targeted apoptosis inducer||Please refer to Note||IV||Phase 2||Indication: Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) and other hematological cancers
Note: No approved drugs for PTCL indication in Europe (3 drugs have been approved in Japan and US).
Less toxic compared with competitors approved in Japan and US.
US Phase 2a: 5 responders in 11 refractory PTCL and DLBCL patients, and 2 responders in 7 PTCL patients. Applicable to relapsed and refractory PTCL.
Phase 2 Pan-Asia pivotal study is ongoing.
Can be licensed to US/EU and China.
|12/10/18||GEM051||Protective agents from heat stress||Heatstroke||Oral||Preclinical||Suppression of vascular endothelial cell damage and production and release of inflammatory cytokines from blood cells due to heat stress.
Ingredients derived from citrus fruit extract.
|11/22/18||GEM050||Curcumin analogue||CML, Pancreatic cancer, glioblastoma etc.||Oral||Preclinical||Inhibited proliferation of CML and pancreatic cancer cells at the submicromolar level.
Unlike imatinib, the inhibitory action is irreversible.
Suppressed almost completely human CML cell growth without significant changes in body weight and peripheral white blood cell count in vivo.
An incease in ROS/RCS produced by inhibition of their scavenging enzymes is assumed to be involved in anti-tumor action.
Induced M phase arrest.
|11/15/18||GEM049||Pan-NOX inhibitor||IBD, Neuro- degenerative diseases||Oral||Preclinical||Highly potent NOX inhibitor : 20-50 times more potent than GKT-137831.
Significant effects in DNBS-ulcerative colitis and LPS-induced acute inflammatory animal studies.
High oral bioavailability and clean off-targets profile.
|11/15/18||GEM048||Inhibition of microbe-specific activation of B2 cells||Arterio- sclerosis||Discovery||Activation of B2 cells induced by changes of intestinal microbiota is involved in the development of atherosclerosis with a different mechanism from lipid metabolism.
Disruption of intestinal microbiota or depletion of activated B2 cells suppressed the development of atherosclerosis in mouse model.